Tamiflu might be the most heavily scrutinized drug in the world and one that governments have poured some $9 billion globally to stockpile in case of a pandemic. However, authors of a new study, published in the British Medical Journal this week, suggest the influenza antiviral probably works no better than Aspirin and possibly causes harm.
The findings are not entirely new. Since 2009, the Cochrane Collaboration—a non-profit research group that produces widely respected summaries of medical evidence, including the latest BMJ study—has been arriving at discouraging conclusions about Tamiflu. Still, governments around the world, including Canada’s, continued to stockpile for an emergency.